EUVIMEDEUVIMED entdecken
Open Access

SARS-CoV-2 B Epitope-Guided Neoantigen NanoVaccines Enhance Tumor-Specific CD4/CD8 T Cell Immunity through B Cell Antigen Presentation

Chengyi Li iD, Fang Ke, Shuai Mao, Zera Montemayor, Mohamed Dit Mady Traore, Alejandra Duran Balsa, Mahamadou Djibo, Neha Karekar, Hongxiang Hu, Hanning Wen, Wei Gao iD, Duxin Sun iD

ACS Nano · 25.02.2025 · 19 (7) · 7038-7054

DOI: 10.1021/acsnano.4c15113 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, online erschienen am 13.02.2025. Verfasst von Chengyi Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, SARS-CoV-2, Epitopes, B-Lymphocyte, Antigen Presentation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesSARS-CoV-2Epitopes, B-LymphocyteAntigen PresentationCancer VaccinesCD4-Positive T-LymphocytesB-LymphocytesCOVID-19Antigens, NeoplasmAnimalsMiceHumansFemaleMice, Inbred C57BLNeoplasmsCell Line, TumorNanovaccines

Stichwörter der Autor:innen

B cell receptor cross-linkingB cell-dependent tumor-specific CD8 T cell immunityB cell-mediated antigen presentationSARS-CoV-2 B cell epitopeneoantigen peptide/mRNA cancer nanovaccinetumor immunotherapytumor-specific follicular/nonfollicular CD4 T cells

Substanzen

Epitopes, B-LymphocyteCancer VaccinesAntigens, NeoplasmNanovaccines

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.
  • Department of Pharmacology and Pharmaceutical Science, College of Pharmacy, The University of Houston, Houston, Texas 77204, United States.

ORCID-Profile: Chengyi Li, Wei Gao, Duxin Sun

Förderung

  • NCI NIH HHS
  • National Institutes of Health

Zitieren

APA

Li, C., Ke, F., Mao, S., Montemayor, Z., Traore, M. D. M., Balsa, A. D., Djibo, M., Karekar, N., Hu, H., Wen, H., Gao, W., & Sun, D. (2025). SARS-CoV-2 B Epitope-Guided Neoantigen NanoVaccines Enhance Tumor-Specific CD4/CD8 T Cell Immunity through B Cell Antigen Presentation. ACS Nano, 19(7), 7038-7054. https://doi.org/10.1021/acsnano.4c15113

Vancouver

Li C, Ke F, Mao S, Montemayor Z, Traore MDM, Balsa AD, et al. SARS-CoV-2 B Epitope-Guided Neoantigen NanoVaccines Enhance Tumor-Specific CD4/CD8 T Cell Immunity through B Cell Antigen Presentation. ACS Nano. 2025;19(7):7038-7054. doi:10.1021/acsnano.4c15113

BibTeX
@article{Li2025,
  author = {Li, Chengyi and Ke, Fang and Mao, Shuai and Montemayor, Zera and Traore, Mohamed Dit Mady and Balsa, Alejandra Duran and Djibo, Mahamadou and Karekar, Neha and Hu, Hongxiang and Wen, Hanning and Gao, Wei and Sun, Duxin},
  title = {SARS-CoV-2 B Epitope-Guided Neoantigen NanoVaccines Enhance Tumor-Specific CD4/CD8 T Cell Immunity through B Cell Antigen Presentation},
  journal = {ACS Nano},
  year = {2025},
  volume = {19},
  number = {7},
  pages = {7038--7054},
  doi = {10.1021/acsnano.4c15113}
}
Kostenlos starten →